Study Status: ACTIVE_NOT_RECRUITING
Recruit Status: ACTIVE_NOT_RECRUITING
Study Type: INTERVENTIONAL
Official Title: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With
Brief Summary: The purpose of this clinical trial is to evaluate efficacy and safety of once weekly SC doses of 100 �g CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia.
The double-blind, placebo-controlled treatment period is followed by an Open Label Extension (OLE) period of a 52-week duration.